Akebia Therapeutics (STU:AX9) Change In Receivables : €-7.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Change In Receivables?

Akebia Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was €11.7 Mil. It means Akebia Therapeutics's Accounts Receivable declined by €11.7 Mil from Dec. 2023 to Mar. 2024 .

Akebia Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €0.9 Mil. It means Akebia Therapeutics's Accounts Receivable declined by €0.9 Mil from Dec. 2022 to Dec. 2023 .

Akebia Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was €24.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Akebia Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 74.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akebia Therapeutics's liquidation value for the three months ended in Mar. 2024 was €-163.8 Mil.

Akebia Therapeutics Change In Receivables Historical Data

The historical data trend for Akebia Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Change In Receivables Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-19.98

9.59

-21.26

10.66

0.91

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															20.13	-0.78	-2.83	-15.31	11.66

Akebia Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.3 Mil.

Akebia Therapeutics (STU:AX9) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akebia Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	24.49	/	29.998	*	91
=	74.50

2. In Ben Graham's calculation of liquidation value, Akebia Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Akebia Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	38.604	-	232.516	+	0.75 * 24.49	+	0.5 * 23.489
=	-163.8

Akebia Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (STU:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AKBA:USA AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines